Intestinal epithelial cells (IECs) secrete cytokines that recruit immune cells to the mucosa and regulate immune responses that drive inflammation in inflammatory bowel disease (IBD). However, experiments in patient-derived IEC models are still scarce. Here, we aimed to investigate how innate immunity and IEC-specific pattern recognition receptor (PRR) signaling can be involved in an enhanced type I interferon (IFN) gene signature observed in colon epithelium from patients with active IBD, with a special focus on secreted ubiquitin-like protein ISG15.
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Introduction
Recent evidence suggests that the intestinal epithelium contributes to the development and perpetuation of inflammation in the inflammatory bowel diseases (IBD), ulcerative colitis (UC) and
Crohn's disease (CD) 1, 2 . In addition to having barrier functions, intestinal epithelial cells (IECs) act as both sensors for pathogen-or damage associated molecular patterns (PAMPs or DAMPS) and as regulators of immune cells 3, 4 . Binding of exogenous PAMPs or endogenous DAMPS to pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs), initiate a number of intracellular signaling cascades via e.g., the transcription factor complexes nuclear factor kappa-light-chainenhancer of activated B cell (NF-κB), mitogen-activated protein kinases (MAPKs) or interferon regulatory factors (IRFs). Activation of NF-κB and MAPKs in IECs induces secretion of interleukins and chemokines, whereas IRFs are more involved in stimulation of interferon (IFN) production and induction of IFN-stimulated genes (ISGs) 5, 6 . IFNs are classified into 3 types: Type I (13 subtypes of IFN, single members of IFN κ, ω, ε, δ, and τ), Type II (IFN) and Type III (IFNλ1, IFNλ2, and IFNλ3) 7 .
Upon external stimuli, IECs have potential to secrete chemokines that can both recruit immune cells and directly induce secretion of inflammatory cytokines which augment and prolong inflammatory responses. For example C-X-C Motif Chemokine Ligand 8 (CXCL8) secreted from IECs and immune cells is considered to be a major chemotactic factor which can attract e.g. CXCR1(+)CXCR2(+)IL- 23- producing neutrophils that infiltrate and accumulate in inflamed colon tissue 8 . Previous work from our group has shown that extracellular stimulation of TLR3 can mediated release of immunomodulatory C-X-C Motif Chemokine Ligand 10 (CXCL10) 9 and Chemokine (C-C motif) ligand 20 (CCL20) 10 from colonic epithelial cells. A recent study showed that the human colonic epithelial cell line NCM460 transfected with the TLR3 ligand poly(I:C) released exosomes containing canonical type I IFN-induced antiviral ISGs such as Ubiquitin-like protein ISG15 11 . To our knowledge, no study regarding release of ISG15 from primary human IECs upon external stimuli has been reported. ISG15 exists in three forms: conjugated to proteins (ISGylation), unconjugated intracellular and secreted free forms 12 . There appears to be functional diversity between species 13, 14 , and in humans several immunomodulatory functions of secreted free ISG15 have been postulated, including chemotaxis of neutrophils 15 , recruitment of IL1producingCD8+ dendritic cells 16 and release of IFN  and IL10 19, 20 from lymphocytes. Recently, Swaim et al 19 showed that extracellular ISG15
regulates IFN and IL10 secretion from the Natural killer (NK) cell line NK-92 through the leukocyte function-associated antigen-1 (LFA-1) integrin receptor. The LFA-1 has two subunits, CD11a(L integrin) and CD18(2 integrin) encoded by the ITGAL and ITGB2 genes, respectively. Swaim et al 19 suggest that direct binding of ISG15 to CD11a signals and activates SRC family kinases (SFKs), leading to secretion of IFN and IL10. In their model, IL12 drives cytokine expression while ISG15 enhances cytokine secretion.
IEC-derived cytokines that augment and prolong inflammatory responses during active IBD are potential targets for immunotherapy. Gene lists in omics studies from our group 21 and others [22] [23] [24] show enhanced expression of ISG15 mRNA in active IBD and experimental murine colitis. Even though ISG15 may boost mucosal immune activity, ISG15 has not been investigated in the context of primary colonic epithelial cells and IBD. Here, we show increased expression of canonical type I IFN 
Materials and Methods

Ethics
The study was approved by the Regional Committee for Medical and Health Research Ethics (Reference numbers 5.2007 .910 and 2013/212/REKmidt) and was registered in the Clinical Trials Protocol Registration System (identifier NCT00516776). All subjects included in the study gave informed written consent.
Clinical material
Patients admitted to St. Olav's University Hospital, Trondheim, Norway for colonoscopy were included after informed consent. They were diagnosed with UC or CD or underwent colonoscopy due to gastrointestinal symptoms with no significant pathology being found. Patients using immunomodulants such as azathioprine or TNF-blockers were excluded. Colonic pinch biopsies (Sample set I) and peripheral blood mononuclear cells, PBMCs, (Sample set II), were collected as described previously 21, 25 .
Sample set I: The colonic pinch biopsies were from a previously described cross sectional study biobank 21 
Experiments in HT29 human intestinal epithelial cells
Experiments in human 3D colonoids
Human 3D colonoid cultures were established from colonic pinch biopsies taken from three non-IBD healthy controls, using an optimized protocol from Mahe et al 26 Recombinant Human Noggin (0.1g/ml))(#120-10C) from PeproTech (Rocky Hill, NJ, USA) and other factors critical for stem cell growth, as described 26 . For establishment of colonoids from crypts, the complete medium was supplemented by the GSK3 inhibitor (i.e. Wnt-activator) CHIR99021
(0.86g/ml)(#72052), and Thiazovivin (0.778g/ml)(#72252), an inhibitor of Rho-associated coiledcoil containing protein kinase (ROCK), both from STEMCELL Technologies.
Undifferentiated cultured colonoids were passaged and expanded every 7 to 10 days after plating, or frozen for biobanking, as described 26 
Experiments in PBMCs
Human PBMCs (Sample set II) were prepared and thawed as previously described 25 . For stimulation experiments, recombinant human ISG15 (500ng/mL) and/or recombinant human IL12 (20ng/mL) were added for 48h before conditioned medium was harvested and stored at -80⁰C.
Flow cytometry: PBMC subpopulations in 35 samples (Sample set II) had previously been identified by flow cytometry analysis 25 , and the data was used for correlation analyses in the present study.
Detailed description of antibody-staining and compensation controls are given in Skovdahl et al 25 .
Flow cytometry was performed on a BD FACS Canto II flow cytometer with FACS Diva software from BD Bioscience (10,000 events per sample) and samples were analysed using FlowJo v10 software from Flow Jo, LLC. ISG15 only if the enhanced cytokine concentration in conditioned medium was above 1000pg/ml compared to untreated control in the multiplex assay.
Enzyme-linked immunosorbent assay (ELISA) and Multiplex chemokine profiling
RNA extraction and gene expression analysis
The following kits were used for RNA extraction, according to the manufacturer's protocol: Ambion mirVana mRNA isolation kit (Applied Biosystems) (human biopsies), RNeasy micro plus (#74034, Qiagen) (microdissected epithelial monolayer), RNeasy Mini kit (#74106, Qiagen) (HT29-cells and colonoids) and RNeasy mini kit and QiaShredder columns (#ID:79654, Qiagen) (PBMCs).
Microarray gene expression analysis of the human colonic biopsies (Sample set I) has previously been described 21 For RT-qPCR of ITGAL and ITGB2 expression in PBMCs (Sample set II) RNA extraction and reverse transcription were done as previously desrcibed 25 . cDNA was analysed for LFA-1 subunits ITGAL and (Applied Biosystems) were used for all PCR procedures.
Bioinformatics and Gene set enrichment analysis
In general, expression analysis was done in the R software environment for statistical computing 29 .
Analysis of the microarray gene expression data from Sample set I has been previously described 21 .
For gene expression analysis in colonic pinch biopsies, LCM epithelial monolayer and colonoids, differential expression between groups were identified using LIMMA linear models with least squares regression and empirical Bayes moderated t-statistics 30 . Temporal gene expressions in treated and untreated HT29-cells were identified using LIMMA linear models with least squares regression and empirical Bayes moderated nested F-statistics 30 . P-values were adjusted for multiple comparisons using the Benjamini Hochberg false discovery rate correction (FDR). Enrichment analyses were done by MetaCore TM version 6.34 build 69200.
Western blotting
Cells were washed twice in ice-cold PBS before they were lysed for 2h on ice in lysis buffer (50mM Tris-HCl pH 7.5, 150mM NaCl, 5mM EDTA, 1% NP-40, 1mM DTT, 1xComplete® EDTA-free protease inhibitor, and 1x phosphatase inhibitor cocktail I and III, respectively (Sigma-Aldrich, Missouri, USA).
Protein lysate was obtained by centrifugation at 14,000xg for 20 min at 4⁰C and protein concentration measured using the Bradford protein assay (Bio-Rad). Conditioned media from HT29cells was concentrated from 500μL to 50μL using Amicon ® ultra-0.5 centrifugal filter devices, 10,000 NMWL (Millipore) according to the manufacturer's recommendations.
Samples were denatured in 1xNuPage LDS sample buffer supplemented with 40mM DTT for 10 min at 70⁰C before they were separated on 4-12% NuPage Bis-Tris gels (Invitrogen) and electroblotted onto Immobilon PVDF membranes (Millipore). The membranes were blocked using 5% BSA in PBS/0.01% Tween 20 (PBS-T) and incubated with primary antibodies as listed in Supplementary 
Immunohistochemistry and In situ hybridization of human biopsies and colonoids
The human colonic biopsies were fixed in 10% buffered-formalin for 3-6 days before embedding in paraffin. For fixation of human colonoids, the Matrigel was depolymerized using Cell Recovery Solution, and the colonoids were washed with PBS and centrifuged (500xg) three times. The colonoid-pellets were either resuspended in 50 l Richard-Allan Scientific™ HistoGel™ Specimen
Processing Gel (# HG-4000-012, Thermo Fisher Scientific) or small amounts (1:5l) of plasma and thrombin that was allowed to coagulate before the pellets were fixed in formalin for 48h and embedded in paraffin. The formalin-fixed, paraffin-embedded (FFPE) biopsies or colonoids were cut into 4µm sections before standard pre-treatments and staining with hematoxylin and eosin.
FFPE sections were processed through standard de-paraffinization and quenching of endogenous peroxidase before immunohistochemistry (IHC). Antigen retrieval was achieved by 15 min boiling in citrate buffer (pH 6.0) (a-ISG15, E-cadherin) or Tris-EDTA buffer (pH 9.0) (a-pSTAT, a-CD11a, a-FABP1, a-MUC2, a-CgA) using a commercial microwave. All sections were incubated overnight at 4 °C with primary antibodies diluted in PBS with 0.25% Triton-X and 0.25% BSA. Primary antibodies and dilutions are listed in Supplementary Table 2 . Immunoreactions were visualized using the rabbit/mouse EnVision-HRP/DAB+ kit (#K5007, Dako) and counterstaining with hematoxylin.
Negative controls were omission of primary antibody and similar concentration of identical nonimmunized IgG.
In situ hybridization (ISH) was performed with the RNAscope 2.5 HD Reagent Kit (Brown) for FFPE tissue (#322300) and human ISG15 probe (#467741) (Advanced Cell Diagnostics Inc. (ACD)) according to the manufacturer's instructions. Images were captured using Nikon E400 microscope, DS-Fil U2 camera and NIS-Elements BR imaging software (Nikon). Further processing was done using Fiji 31 .
Statistical analyses
Except for the global gene expression analyses described in Method section 2.9, statistical analyses were performed in GraphPad Prism 8.0 (GraphPad Software Inc., San Diego, CA, USA). For numerical values and log2 transformed data, differences between groups were evaluated by analysis of transcription of ISGs 32 . The upregulated ISGs shown in Figure 1 have been reported to be strongly enriched for the ISGF3-binding ISRE motif 33, 34 .
To examine whether the ISGs were produced by IECs, we analyzed an in-house RNASeq-dataset showing gene expression in laser captured microdissected epithelial monolayer from inflamed, active IBD (n=12) versus uninflamed IBD (n=11) and non-IBD controls (n=6). Several type I IFN genes (IFNAR2, STAT1, IRF1, ISG15, ISG20, IFI16, IFIT3, IFITM1, IFITM2, IFITM3 OAS2, OAS3 and USP18)
were upregulated also in the separated IECs during active IBD (Figure 2A and Supplementary file 2).
Since ISG15 in particular has potential to boost IBD relevant immune activities 12, 19 , we proceeded to examine localization of pSTAT1, ISG15 proteins and the ISG15 binding receptor unit CD11a (ITGAL) 19 in colon mucosa biopsies from non-IBD controls and active IBD by IHC ( Figure 2B -D). While we observed increased levels of pSTAT1 and ISG15 in the colonic epithelium monolayer from active IBD compared to non-IBD controls, the newly identified receptor subunit for extracellular ISG15, CD11a 19 , was mainly restricted to lamina propria cells. This is in line with the gene expression data from microdissected colonic epithelial lining (Figure 2A ). The IEC localization and increased expression of ISG15 in active UC and CD were confirmed by ISH examining ISG15 mRNA ( Figure 2E ).
Since ISG15 can enhance IL12-induced IFN release  and IFN is upregulated in mucosa during active IBD 9 , we analyzed correlation between expression of ISG15, IFN and the LFA-1 receptor units ITGAL and ITGB2 in mucosa from non-IBD controls (n=20) and inactive (n=65) and active IBD (n=49).
We found a significant correlation between ISG15 and IFN mRNA expression in inactive (r=0.34, p=0.0064) and active (r=0.5, p<0.0001) IBD that was not observed in controls (r=0.17, p=463) ( Figure   2F ). Expression of ISG15 mRNA correlated strongly with both ITGAL ( Figure 2G ) and ITGB2 ( Figure   2H ) mRNA when analyzing all individuals (n=134). Overall, this indicated a possible correlation 
Poly(I:C) and TNF activate type I IFN signaling pathway and successive regulation of ISG15 in HT29 human intestinal epithelial cells
To investigate whether innate immunity and IEC-specific PRR-signaling could contribute to type I IFN signaling pathway and regulation of ISG15 in IECs during IBD, we first performed a transcriptome time-series screen in colonic epithelial HT29-cells treated with TLR1-9 ligands, NOD2-ligand, IL10, IL1 or TNF. HT29-cells showed strongest response to TNF, IL1, poly(I:C) (TLR3), Flagellin (TLR5) and
LPS (TLR4), as demonstrated by induction of mRNAs coding for the IBD-related chemokines CXCL8
and CXCL10 (Supplementary Figure 1A) . Gene enrichment analysis revealed that TNF, IL1and the TLR3 ligand poly(I:C) elicited canonical type I IFN signature genes that encode antiviral and inflammatory mediators 32, 35 (Supplementary Figure 1B and Supplementary file 3) . Both regulatory and effector ISGs 33 were significantly induced by the three ligands compared to untreated controls ( Figure 3A ).
We then continued to examine regulation of ISG15 protein expression by TNF, poly(I:C) and IL1 in HT29-cells. Western blot analysis confirmed phosphorylation of STAT1 and expression of IRF9 and intracellular free ISG15 protein in poly(I:C), IL1 and TNF treated HT29-cells, as well as after treatment with the known IFNAR ligand IFN used as positive control ( Figure 3B ). We detected significantly enhanced levels of intracellular free ISG15 in the ligand treated cells at 24h ( Figure 3C ). including intracellular and secreted free ISG15, were strongly impaired after pharmacologically blocking the JAK-STAT pathway, indicating that the signaling went through JAK1. We also detected small amounts of poly(I:C)-induced IFNin up-concentrated medium (1:5), which was again reduced by JAK inhibition (Figure 3E ). When we pretreated the cells with neutralizing antibody against IFN 1h before ligand stimulation, the levels of pSTAT1, IRF9 and free ISG15 in TNF and IFN treated cells were almost similar to untreated controls ( Figure 3F-G) , indicating that the signaling went through IFNAR/JAK, as illustrated in Supplementary Figure 1D . In poly(I:C) treated cells, densitometric analysis of intracellular expression of free ISG15 protein and detection of free ISG15 in conditioned medium by ELISA showed that the response was only partly impaired by neutralizing antibody against IFN vs. IgG isotype control ( Figure 3G-H) . This is in line with other in vitro studies showing that some poly(I:C)-induced antiviral genes, including CXCL10 and ISG15, can be activated directly by TLR3-signaling, as well as by autocrine IFN-signaling 36, 37 . Overall, our results showed that extracellular TNF and poly(I:C) activated type I IFN-signaling through JAK1-pSTAT-IRF9 with successive induction of both intracellular and secreted free ISG15 in HT29-cells. In addition, free ISG15 can be induced by IFN-independent signaling.
Human 3D colonoids release free ISG15 upon extracellular stimulation
To examine if poly(I:C) and TNF also could induce type I IFN signature genes in a more physiologically relevant model, we performed additional experiments in primary human 3D colonoids established from colonoscopic pinch biopsies 26 . The colonoids were expanded and differentiated into 3D multicellular structures containing absorptive, goblet and enteroendocrine cells ( Figure 4A ). After having established that the human colonoids were responsive to poly(I:C) and TNF treatment (Supplementary Figure 3A Figure 3B) . While TNF induced fewer ISG mRNAs in human colonoids than in the cell line HT29 (Supplementary file 4) , several ISGs, including ISG15, were significantly up-regulated in colonoids treated with poly(I:C) for 6 and 24h ( Figure 4B ).
We then examined whether ISG15 protein expression was enhanced in the colonoids after extracellular stimulation. IHC staining showed varying intensities of both nuclear (ISGylation) and cytoplasmic ISG15 expression in poly(I:C), poly(I:C)+TNF and IFN treated colonoids at 24h ( Figure   4C ). ISG15 seems to be expressed in both goblet cells and absorptive cells.
Western blot analysis showed that Poly(I:C) induced pSTAT1, IRF9 and free ISG15 proteins ( Figure   4D -E), but with different time-dependent expression than the positive control: In IFN treated cells,
pSTAT was detected as early as 10min ( Figure 4D) , while a similar level of pSTAT was not detected until 3-6h after poly(I:C) treatment ( Figure 4E ). Organoids pretreated with neutralizing antibodies against IFN prior to IFNtreatment had reduced levels of pSTAT1, total STAT1, IRF9 and intracellular and secreted free ISG15 at 24h ( Figure 4F ). Levels of the same proteins were not impaired in colonoids pretreated with antibody against IFN before poly(I:C) treatment ( Figure 4F ); and we were not able to detect poly(I:C) induced regulation of IFNmRNA in colonoids. This indicated that poly(I:C) can induce ISG15 independent of an autocrine/paracrine type I IFN signaling loop in both primary human IECs and HT29 cells. In line with the observed nuclear staining of ISG15 by IHC ( Figure 4C ), IFN and poly(I:C) induced ISGylation as well as intracellular and secreted free forms of ISG15 in human colonoids ( Figure 4F -H and Supplementary Figure 4) . Interestingly, only intracellular and secreted free ISG15 were observed in HT29-cells ( Supplementary Figure 3) .
Densitometric analysis of western blots of whole cell lysates showed that while TNF induced only minor expression of intracellular free ISG15 protein at 24h, we observed a variable, but significant expression of free ISG15 in poly(I:C) treated colonoids, and a robust and relatively high expression of free ISG15 in IFN treated colonoids Figure 4G). ELISA analysis showed that free ISG15 was released to the medium after treatment with TNF and poly(I:C) as well as IFN ( Figure 4H ).
Overall, RNASeq-data, IHC and western blot analysis showed that the type I IFN gene signature and ISG15 protein expression observed in human mucosal biopsies (Figures 1 and 2) were mimicked in human epithelial 3D colonoids (Figure 4 ) which are devoid of any immune cells. We also demonstrated that ISG15 can be secreted from primary IECs after extracellular stimulation. 
Correlation between expression of the LFA-1 receptor unit ITGAL and ISG15-regulated release of IFNfrom PBMCs
Since IL12 and IFNas well as the LFA-1 receptor unit CD11a (ITGAL) are well known IBDsusceptibility genes 38, 39 , it was of interest to analyse if extracellular ISG15 could modulate IL12 induced release of IFN in immune cells from IBD patients. We first confirmed 14, 19 that extracellular ISG15 and IL12 reproducibly and synergistically stimulate release of IFN in PBMCs derived from three healthy donors ( Figure 5A ). We then proceeded to measure IFN release from PBMCs isolated from non-IBD controls (n=6), inactive IBD (n=16) and active IBD (13) after treatment with ISG15, IL12 or ISG15+IL12 combined. While PBMCs from both non-IBD controls and IBD-patients showed almost undetectable basal and ISG15-induced levels of IFNrelease into mediaIL12 induced variable release of IFN from PBMCs derived from different individuals, ranging from 67-10.500 pg/ml (Supplementary Figure 5 ). Although we observed great inter-individual differences in sensitivity to IL12 and ISG15 treatment within all groups, 83% and 55% of PBMC-cultures from non-IBD controls and IBD, respectively, showed enhanced IFN release after ISG15+IL12 treatment compared to IL12 alone ( Figure 5B ). It has been reported that IFN is released mainly from Natural killer (NK) cells and T-cells upon presence of ISG15 and IL-12, although unsorted PBMCs respond better to ISG15+IL12 than fractioned primary NK or T-cells 14 . We therefore examined whether the variations in synergistic release of IFNwas due to the relative frequency of PBMC subpopulations present in the individual samples, using flow-cytometric analysis 25 . However, we did not find any correlation between IFN release in response to IL12+ISG15 vs. IL12 alone and frequency of CD16+ NK-cells or other PBMC subpopulations (CD4+, CD8+, CD19+ and CD14+) in PBMCs ( Figure 5C ).
We then examined for a possible correlation between ISG15 modulated secretion of IFN and expression of LFA-1 subunits in the cells. Expression levels of ITGAL and ITGB2 ( Figure 5D ) mRNAs in PBMCs derived from the same sample population used in the stimulation experiments shown in Figure 5B were quantified by RT-qPCR. The expression of both subunits was mostly equal in the different groups. When we linked expression levels of ITGAL and ITGB2 mRNAs with release of IFNfrommatching PBMC samples after treatment with IL12+ISG15 vs. IL12 alone, we found a significant correlation between ITGAL expressions in PBMCs and IFN concentrations in culture media (r=0.39; p=0.02) ( Figure 5E ).
ISG15 boosts release of several IBD-related cytokines from PBMCs
To investigate whether ISG15 could regulate secretion of additional IBD-related cytokines, PBMCs from three healthy donors were treated with recombinant human ISG15, IL12 or IL12+ISG15 combined for 48h and secreted cytokines were detected by the Bio-Plex Pro Human Chemokine Panel featuring 40 magnetic bead-based immunoassays. Consistent with findings by others 14, 19, 20 , IL12+ISG15 combined elicited a strongly synergistic effect on the secretion of IFN, and ISG15 alone induced IL6 ( Figure 6A ) and IL10 (Supplementary Figure 6) . Additionally, we found that IL12 alone induced strong release of CXCL9 and CXL10 and that ISG15 appeared to be a very potent modulator for several other IBD-related cytokines (Figure 6A, Supplementary Figure 6 ). Using a relatively strict selection criterion as described in the Method section, the 40-plex analysis indicated that ISG15 modulated release of CXCL1, CXCL2, CXCL5, CCL1, CCL3, CCL7, CCL8, CCL20, CCL25, IL1, IL6 and TNF.
In addition, high levels of CXCL8 (out of range) were observed (Supplementary Figure 6) . Robust ISG15 and/or IL12 induced secretion of TNF, CCL20, CXCL8 and CXCL10 were confirmed by ELISA analysis of conditioned media from 4-5 independent experiments performed on PBMCs from three other healthy donors ( Figure 6B ). Overall, these results suggest that ISG15 can potentiate the release of IBD-related cytokines.
Discussion
In this study we show an increased expression of type I IFN related ISGs in colon epithelium from patients with active IBD. The group of ISGs found to be upregulated during active disease is included in a subset of ISGs strongly enriched for the ISRE promoter element 33,34 that Mostafavi et al 33 defined as sensitive to tonic type I IFN signals at baseline. We did not detect enhanced IFNmRNA in colonic mucosa during active IBD, but the overall mRNA abundance for IFNmRNA is minute and close to the lower end of the dynamic range of the gene expression assay used. The problem of measuring IFN regulation directly is well known and has been encountered in previous studies 40 , and IFN is found distributed in epithelium and lamina propria in human colonic tissue. 41 Although we, like others, were unable to show that IFN gene expression is regulated during inflammation, the transcriptional pattern observed in active IBD is consistent with a robust interferon response.
In humans, the impact of type I IFN signaling is reported to be both pro-and anti-inflammatory 7, 40, 42 .
Slight alterations in the type I IFN signaling network may contribute to imbalanced immune responses in IBD 7 , but the role of type I IFNs and ISGs in IECs during IBD in the human has not been thoroughly investigated. It has been suggested that constitutive type I IFN signaling induced by the microbiota modulates homeostatic balance through tonic signaling in a cell and context dependent manner 34, 43 . Low constitutive amounts of IFN in the absence of acute infections can prime cells in and IL12 treated PBMCs derived from non-IBD controls and IBD-patients. We found that ISG15modulated secretion of IFN correlated weakly, but significantly with mRNA expression levels of the LFA-1 integrin receptor unit CD11a (ITGAL) in PBMCs. The LFA-1 integrin receptor is expressed on Tcells, B-cells, macrophages, neutrophils and NK-cells 47 . In the context of IBD, LFA-1 on T-cells is best known as receptor for ICAM1. Swaim et al 2017 19 showed that extracellular ISG15 induces IFN and IL10 secretion through the LFA-1 integrin receptor in a NK-92 cell line-based assay and in CD11a KO mice, but no data regarding ISG15 receptors on human primary cells are published. Our transcriptome data from human colon biopsies indicated a correlation between ISG15 and ITGAL expression and enhanced expression of IFN in colon mucosa during active IBD. While more investigation is needed to address ISG15 receptors on human primary immune cells, we propose a model based on our data and literature 12, 19 where dsRNA(TLR3), PAMPs or DAMPs signaling and induced ISGs contribute to inflammation in active IBD by e.g. enhanced expression of IECs-derived free ISG15. Secreted free form of human ISG15 can boost IBD relevant immune activities, including chemotaxis of neutrophils 15 and regulation of cytokines such as IFN, CXCL1, CXCL5, CXCL8, CCL20, TNF, IL6 and IL1 released from infiltrating immune cells ( Supplementary Figure 7) . At date, around 240 single nucleotide polymorphisms (SNPs) associated with increased IBD risk have been identified, comprising genes related to intestinal epithelial function, as well as innate and adaptive immune responses 38, 39, 48, 49 . Central genes in the IFNAR1-STAT1-ITGAL-ISG15-cytokine network are associated with IBD-related genetic polymorphisms (SNPs) 38, 39, 48 , such as IFNAR1 (rs2284553), STAT1 (rs1517352), IRF1 (rs2188962), IL12B (rs6871626), IFN(rs7134599), ITGAL (rs11150589), the major ligand for LFA-1 on T-cells: ICAM1 (rs5498), IL12B (rs6871626), CCL20 (rs111781203 48 _ rs1811711 39 ), and the chemokines CXCL1, CXCL5 and CXCL8 (all rs2472649).
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